COVID-19 drug trial halted early: aprepitant shows no clear benefit
Disease control
Terminated
This study tested whether the drug aprepitant could help hospitalized COVID-19 patients recover faster. The trial was stopped early after enrolling only 27 people. Researchers aimed to see if the drug reduced the need for breathing support or shortened hospital stays.
Phase: PHASE2 • Sponsor: Heron Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:54 UTC